Haloperidol Decanoate 100 mg/mL (Haloperidol Decanoate INJECTION) 100 mg/mL

Haloperidol Decanoate 100 mg/mL is an injectable medication used for managing certain mental health conditions. This long-acting formulation is administered intramuscularly and is manufactured by Hikma Pharmaceuticals USA Inc.

Strength

100 mg/mL

Pack Size

1 VIAL in 1 BOX (0143-9296-01) / 5 mL in 1 VIAL

Manufacturer / TM Owner

Hikma Pharmaceuticals USA Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Haloperidol Decanoate is primarily used for the treatment of schizophrenia and other psychotic disorders. It is also used to manage severe behavioral problems in individuals who have not responded to other treatments. This medication works by affecting the balance of natural chemicals in the brain.

Side Effects

Common effects of Haloperidol Decanoate may include drowsiness, dizziness, and restlessness. Some individuals may experience weight gain, tremors, or muscle stiffness. It is important to discuss any persistent or severe side effects with a healthcare provider.

Precautions & Warnings

Haloperidol Decanoate should be used with caution in individuals with a history of heart problems, seizures, or Parkinson's disease. It is important to inform your healthcare provider about any allergies or other medications you are taking before starting this treatment.

Avoid Interactions

Haloperidol Decanoate may interact with other medications, including those that affect the central nervous system, such as antidepressants, sedatives, and alcohol. It is important to discuss all current medications with your healthcare provider to avoid potential interactions.

References

Frequently Asked Questions

Haloperidol Decanoate is used to manage schizophrenia and other psychotic disorders, as well as severe behavioral problems in individuals who have not responded to other treatments.

Haloperidol Decanoate is administered as an intramuscular injection by a healthcare professional.

Common side effects may include drowsiness, dizziness, restlessness, weight gain, tremors, and muscle stiffness.

Haloperidol Decanoate may interact with other medications, so it is important to discuss all current medications with your healthcare provider.

Individuals with a history of heart problems, seizures, or Parkinson's disease should use Haloperidol Decanoate with caution and under medical supervision.

Published by GNH India Pharmaceuticals Limited

Last updated: 17 Jun 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.